Regeneron Q1 2026 Earnings: Dupixent Sales Surge 33% to $4.9B, EYLEA HD Shows Strong Growth

Key Takeaways

• Regeneron’s Q1 2026 revenues jumped 19% to $3.6 billion, beating growth expectations
• Dupixent global sales reached $4.9 billion with 33% year-over-year growth, reinforcing its market dominance
• EYLEA HD demonstrated strong market adoption with 52% sales growth to $468 million

---

Regeneron Delivers Strong Q1 2026 Performance

Regeneron Pharmaceuticals reported robust first quarter 2026 financial results on April 29, with total revenues climbing 19% to $3.6 billion compared to the same period in 2025. The biotechnology company’s performance was primarily driven by continued strength in its flagship immunology drug Dupixent and growing adoption of its next-generation eye treatment EYLEA HD.

Dupixent Maintains Market Leadership

Dupixent, developed in partnership with Sanofi, recorded global net sales of $4.9 billion in Q1 2026, representing a substantial 33% increase year-over-year. The atopic dermatitis and asthma treatment continues to expand its market reach as physicians and patients increasingly adopt the therapy for multiple inflammatory conditions.

EYLEA Portfolio Shows Mixed Results

Regeneron’s ophthalmology franchise demonstrated the transition dynamics between legacy and next-generation treatments. EYLEA HD, the company’s high-dose formulation for wet age-related macular degeneration, achieved impressive 52% growth with U.S. net sales reaching $468 million.

However, combined U.S. sales of EYLEA HD and the original EYLEA decreased 10% to $941 million, reflecting the expected cannibalization as patients and physicians migrate to the newer formulation offering extended dosing intervals.

Strong Earnings Performance

The company reported GAAP earnings per share of $6.75, which included a $0.82 negative impact from in-process research and development (IPR&D) expenses. Non-GAAP EPS reached $9.47, also reflecting a $0.80 negative impact from IPR&D investments, demonstrating Regeneron’s continued commitment to pipeline development.

Market Implications

The results underscore Regeneron’s successful execution of its diversified portfolio strategy, with established products like Dupixent driving consistent growth while newer innovations like EYLEA HD gain market traction. The strong financial performance provides the company with substantial resources to advance its extensive clinical pipeline across oncology, immunology, and rare diseases.

---

Frequently Asked Questions

What drove Regeneron’s strong Q1 2026 performance?

The 19% revenue growth was primarily driven by Dupixent’s 33% sales increase to $4.9 billion and EYLEA HD’s 52% growth, demonstrating strong demand for both established and newer treatments.

Why did total EYLEA sales decline despite EYLEA HD growth?

While EYLEA HD grew 52% to $468 million, combined EYLEA franchise sales fell 10% to $941 million due to expected cannibalization as patients transition from the original EYLEA to the newer high-dose formulation.

How does this performance compare to previous quarters?

The 19% revenue growth and strong Dupixent performance of 33% growth indicate continued momentum, with the company successfully executing its strategy of maximizing established products while launching next-generation treatments.